FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W123313263> ?p ?o ?g. }

• W123313263 endingPage "6" @default.
• W123313263 startingPage "S12" @default.
• W123313263 abstract "To compare systemic sclerosis (SSc) patients with and without anti-PM-Scl antibody.We reviewed the medical records of 76 anti-PM-Scl antibody positive SSc patients and 2349 anti-PMScl negative SSc patients first evaluated during 1980-2004. Patients were included if they had a clinical diagnosis of SSc either alone or in overlap with another connective tissue disease. Anti-PM-Scl antibody was screened for by indirect immunofluorescence and tested by Ouchterlony double immunodiffusion.Anti-PM-Scl antibody positive patients had a significantly higher frequency of a positive ANA with nucleolar staining (87% vs. 32%, p<0.0001) and were younger at both symptom onset (p=0.004) and first physician diagnosis of SSc (p<0.001). They were classified more often as having overlap with another connective tissue disease, particularly polymyositis-dermatomyositis, and more frequently had limited cutaneous involvement (72% vs. 52%, p=0.001). Maximal skin thickening was less in anti-PM-Scl antibody patients (mean modified Rodnan total skin score 6.0±6.3 vs. 15.9±14.2, p<0.001). Anti-PM-Scl antibody positive patients less frequently had peripheral vascular (91% vs. 98%, p=0.0002) and gastrointestinal (52% vs. 79%, p=0.0001) disease. Lung involvement overall had a similar distribution between both groups. However, radiographic evidence of pulmonary fibrosis was more frequent in anti-PM-Scl antibody positive patients (50% vs. 37%, p=0.05) and pulmonary arterial hypertension was less often detected (5% vs. 15%, p<0.04). Skeletal muscle involvement (51% vs. 14%, p<0.0001) and subcutaneous calcinosis (p<0.003) were both significantly more often observed in anti-PM-Scl antibody positive patients. Joint, heart, and kidney involvement were similar in both groups. Overall survival was significantly better for anti-PM-Scl antibody positive patients (10 year cumulative survival rate 91% vs. 65%, p=0.0002). After adjustment for age, sex and limited vs. diffuse cutaneous involvement, patients with anti-PM-Scl antibody were significantly less likely to die (HR=0.32, 95% CI, [0.14, 0.72] p=0.006).SSc patients with anti-PM-Scl antibody are younger and significantly more often have limited cutaneous involvement, skeletal muscle disease, pulmonary fibrosis and calcinosis compared to anti-PM-Scl antibody negative SSc patients. Ten-year cumulative survival is significantly better in anti-PM-Scl antibody positive SSc patients." @default.
• W123313263 created "2016-06-24" @default.
• W123313263 creator A5002529289 @default.
• W123313263 creator A5022094279 @default.
• W123313263 creator A5040734260 @default.
• W123313263 creator A5040751341 @default.
• W123313263 creator A5047831622 @default.
• W123313263 date "2012-01-21" @default.
• W123313263 modified "2023-09-23" @default.
• W123313263 title "Anti-PM-Scl antibody in patients with systemic sclerosis." @default.
• W123313263 cites W1429824340 @default.
• W123313263 cites W1573501088 @default.
• W123313263 cites W1712510811 @default.
• W123313263 cites W1808798629 @default.
• W123313263 cites W184510336 @default.
• W123313263 cites W1980442679 @default.
• W123313263 cites W2022171526 @default.
• W123313263 cites W2028009985 @default.
• W123313263 cites W2050238976 @default.
• W123313263 cites W2056351738 @default.
• W123313263 cites W2062886626 @default.
• W123313263 cites W2075204982 @default.
• W123313263 cites W2121599003 @default.
• W123313263 cites W2149839143 @default.
• W123313263 cites W2152348310 @default.
• W123313263 cites W2170484142 @default.
• W123313263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22261302" @default.
• W123313263 hasPublicationYear "2012" @default.
• W123313263 type Work @default.
• W123313263 sameAs 123313263 @default.
• W123313263 citedByCount "20" @default.
• W123313263 countsByYear W1233132632012 @default.
• W123313263 countsByYear W1233132632014 @default.
• W123313263 countsByYear W1233132632015 @default.
• W123313263 countsByYear W1233132632016 @default.
• W123313263 countsByYear W1233132632017 @default.
• W123313263 countsByYear W1233132632019 @default.
• W123313263 countsByYear W1233132632021 @default.
• W123313263 countsByYear W1233132632022 @default.
• W123313263 countsByYear W1233132632023 @default.
• W123313263 crossrefType "journal-article" @default.
• W123313263 hasAuthorship W123313263A5002529289 @default.
• W123313263 hasAuthorship W123313263A5022094279 @default.
• W123313263 hasAuthorship W123313263A5040734260 @default.
• W123313263 hasAuthorship W123313263A5040751341 @default.
• W123313263 hasAuthorship W123313263A5047831622 @default.
• W123313263 hasConcept C126322002 @default.
• W123313263 hasConcept C142724271 @default.
• W123313263 hasConcept C149443304 @default.
• W123313263 hasConcept C159654299 @default.
• W123313263 hasConcept C163764329 @default.
• W123313263 hasConcept C180032290 @default.
• W123313263 hasConcept C198451711 @default.
• W123313263 hasConcept C203014093 @default.
• W123313263 hasConcept C2775941666 @default.
• W123313263 hasConcept C2776670291 @default.
• W123313263 hasConcept C2777543607 @default.
• W123313263 hasConcept C2777714996 @default.
• W123313263 hasConcept C2778751314 @default.
• W123313263 hasConcept C2778962941 @default.
• W123313263 hasConcept C2779075594 @default.
• W123313263 hasConcept C2779134260 @default.
• W123313263 hasConcept C2779387793 @default.
• W123313263 hasConcept C2779967694 @default.
• W123313263 hasConcept C518705261 @default.
• W123313263 hasConcept C71924100 @default.
• W123313263 hasConcept C80020023 @default.
• W123313263 hasConcept C90924648 @default.
• W123313263 hasConcept C91523082 @default.
• W123313263 hasConceptScore W123313263C126322002 @default.
• W123313263 hasConceptScore W123313263C142724271 @default.
• W123313263 hasConceptScore W123313263C149443304 @default.
• W123313263 hasConceptScore W123313263C159654299 @default.
• W123313263 hasConceptScore W123313263C163764329 @default.
• W123313263 hasConceptScore W123313263C180032290 @default.
• W123313263 hasConceptScore W123313263C198451711 @default.
• W123313263 hasConceptScore W123313263C203014093 @default.
• W123313263 hasConceptScore W123313263C2775941666 @default.
• W123313263 hasConceptScore W123313263C2776670291 @default.
• W123313263 hasConceptScore W123313263C2777543607 @default.
• W123313263 hasConceptScore W123313263C2777714996 @default.
• W123313263 hasConceptScore W123313263C2778751314 @default.
• W123313263 hasConceptScore W123313263C2778962941 @default.
• W123313263 hasConceptScore W123313263C2779075594 @default.
• W123313263 hasConceptScore W123313263C2779134260 @default.
• W123313263 hasConceptScore W123313263C2779387793 @default.
• W123313263 hasConceptScore W123313263C2779967694 @default.
• W123313263 hasConceptScore W123313263C518705261 @default.
• W123313263 hasConceptScore W123313263C71924100 @default.
• W123313263 hasConceptScore W123313263C80020023 @default.
• W123313263 hasConceptScore W123313263C90924648 @default.
• W123313263 hasConceptScore W123313263C91523082 @default.
• W123313263 hasIssue "2 Suppl 71" @default.
• W123313263 hasLocation W1233132631 @default.
• W123313263 hasOpenAccess W123313263 @default.
• W123313263 hasPrimaryLocation W1233132631 @default.
• W123313263 hasRelatedWork W123313263 @default.
• W123313263 hasRelatedWork W1997419721 @default.

• next